Rhythm Pharmaceuticals (RYTM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Rhythm Pharmaceuticals faces a business ...

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have earned an average recommendation of “Moderate Buy ...

Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of ...

Handelsbanken Fonder AB lessened its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 11.9% in the 4th quarter, HoldingsChannel reports. The institutional investor ...

Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its fourth quarter and full year 2024 financial results and recent ...

10 analysts have shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:RYTM) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

In the last three months, 7 analysts have published ratings on Rhythm Pharmaceuticals (NASDAQ:RYTM), offering a diverse range of perspectives from bullish to bearish. The following table ...

Good day, and welcome to Rhythm Pharmaceuticals Fourth Quarter and Fiscal Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers ...

BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...